| Title: |
Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial |
| Authors: |
Tuttle, Katherine R.; Mann, Johannes F.E.; Mayrdorfer, Manuel M.; Rayner, Brian; Pugliese, Giuseppe; Pratley, Richard E.; Perkovic, Vlado; Mahaffey, Kenneth W.; Kashihara, Naoki; Jeppesen, Ole K.; Gumprecht, Janusz; Correa-Rotter, Ricardo; Cherney, David Z.I.; Bosch-Traberg, Heidrun; Arici, Mustafa; Rossing, Peter |
| Contributors: |
Novo Nordisk A/S |
| Source: |
Clinical Journal of the American Society of Nephrology ; ISSN 1555-9041 1555-905X |
| Publisher Information: |
Ovid Technologies (Wolters Kluwer Health) |
| Publication Year: |
2026 |
| Description: |
Key Points Semaglutide reduced kidney outcome risk across broad CKD severity strata (eGFR; albuminuria). Reduced risk for all-cause death also carried through strata of CKD severity. In a population with type 2 diabetes, semaglutide improved kidney and survival outcomes irrespective of CKD severity, including advanced CKD. Background Semaglutide improved kidney and overall survival in participants with type 2 diabetes (T2D) and CKD in the Evaluate Renal Function with Semaglutide Once Weekly (FLOW) trial. The aim of the present analyses was to quantify these benefits across broad strata of CKD severity. Methods FLOW was a double-blind, randomized, placebo-controlled trial (median follow-up 3.4 [interquartile range, 2.9–4.0] years). Participants with T2D and eGFR 50–75 ml/min per 1.73 m 2 and urine albumin-to-creatinine ratio (UACR) >300 to |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.2215/cjn.0000000974 |
| DOI: |
10.2215/CJN.0000000974 |
| Availability: |
https://doi.org/10.2215/cjn.0000000974; https://journals.lww.com/10.2215/CJN.0000000974 |
| Rights: |
http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.5658A9A |
| Database: |
BASE |